Efficacy and safety of Ginkgo biloba for patients with early diabetic nephropathy

Abstract

Background: Diabetic nephropathy (DN) is not only an important microvascular complication of diabetes but also the main cause of end-stage renal disease. Ginkgo biloba has a variety of biological activities and has been widely used in China to treat kidney diseases such as DN. This article aimed to evaluate the efficacy and safety of G biloba in patients affected with DN in the early stage. Methods: This protocol follows the preferred reporting items for systematic review and meta-analysis protocols and the recommendations of the Cochrane Collaboration Handbook. Seven electronic databases will be searched from inception to July 31, 2020. Two investigators will independently identify relevant randomized controlled trials, fetch data, and assess the risk of bias with tools provided by Cochrane. A comprehensive meta-analysis will be conducted with the Cochrane Collaboration software (Review Manager 5.3) for eligible and appropriate studies. Further, the evidence will be assessed with the Grading of Recommendations Assessment, Development, and Evaluation approach. Results: The results will be published in academic peer-reviewed journals, and the evidence gathered by this project will be dedicated to assessing the efficacy and safety of G biloba for DN patients in the early stage. Conclusion: This systematic review and meta-analysis will synthesize the available evidence to demonstrate the efficacy of G biloba in delaying the progression of patients with early DN. Trial registration number: PROSPERO CRD42020166805.

Ginkgo Biloba Extract EGB761 Ameliorates the Extracellular Matrix Accumulation and Mesenchymal Transformation of Renal Tubules in Diabetic Kidney Disease by Inhibiting Endoplasmic Reticulum Stress

“…EGB761 contains flavonoids, terpene lactones, organic acids, and other chemical components, and it exerts several effects including antioxidant and free radical scavenging action, circulation improvement, platelet aggregation resistance, and nervous system protection [ 15 ]. Modern studies found that Ginkgo biloba injection significantly reduces 24-hour urinary microalbumin, total cholesterol, and triglyceride and improves renal function [ 16 , 17 ] in DKD patients, as well as relieves their clinical symptoms. However, its specific role and mechanism are needed to be clarified.…”

Heme Degradation in Pathophysiology of and Countermeasures to Inflammation-Associated Disease

“…Currently, Ginkgo biloba is an adaptive species and grows well in most parts of the world, including in the Mediterranean climate. The extract of Ginkgo biloba and/or its ginkgolide components, e.g., EGb761, BN52021, BN5739 and BN52063, possess many beneficial effects on the function of several injured and diseased cells and organs, including the nervous [ 116 , 117 , 118 , 119 , 120 ], renal [ 121 , 122 , 123 ] and cardiovascular [ 124 , 125 , 126 , 127 , 128 , 129 , 130 ] systems.…”

Effects and safety of Ginkgo biloba on blood metabolism in type 2 diabetes mellitus: a systematic review and meta-analysis

“…There is still controversy about the clinical effects of GKB on blood metabolism in patients with T2DM. Some studies have suggested that GKB was beneficial in improving T2DM-related complications ( 2 , 7 , 10 ), but others found that the efficacy of GKB on diabetic macrovascular complications was not yet significant ( 11 ). Therefore, in this study, we analyzed the effects of ginkgo on blood metabolism in diabetic patients based on a large sample with comprehensive parameters.…”

“…A serious concern for healthcare was diabetes mellitus (DM), which has several features including chronic hyperglycemia and aberrant protein, fat, and carbohydrate metabolism (2,(4)(5)(6). Diabetes is one of the five priority noncommunicable diseases (NCDs) in WHO's NCDs control strategy (7,8). Ongoing complex, expensive efforts are required to prevent and treat chronic problems in patients with diabetes, especially type 2 diabetes mellitus (T2DM).…”